sTILs vary markedly across breast cancer subtypes and correlate with aggressive pathological features, particularly TNBC, high-grade, hormone receptor negativity, and high proliferative index. Incorporating standardized sTIL assessment into routine reporting may help identify tumors with active immune microenvironments.
Verma et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: